GIVE YOUR CASE BACKBONE

WITH THE MOST POWERFUL ALL-IN-ONE MEDICAL & LEGAL RESEARCH TOOL

DEEPER MEDICAL AND LEGAL CONTENT

MedMal Navigator® surveyed users believe that the tool's most critical types of content are the medical standards of care and trusted medical content.*



Obtain timely and trusted medical research content:

■ 11K netter

■ 1,600 full-text
MEDICAL JOURNALS

ASSESS CASE VALUE AND COMPARE SIMILAR

VERDICTS & SETTLEMENTS

with the largest collection of documents in the industry.



1.1

Published and unpublished information on over







GREATER VALUE AND EFFICIENCY WITH A SINGLE TOOL



positive RETURN ON INVESTMENT

80% of surveyed users believe

MEDMAL NAVIGATOR PROVIDES

A POSITIVE ROI.

AFFIRMATIVE



83% of surveyed users agree that MedMal Navigator provides attorneys the medical and legal research they need to help achieve positive outcomes for clients.

better decisions

WITH ANALYTICAL TOOLS:



83% of surveyed users from large law firms agreed that MedMal Navigator analytical graphs and charts show results that help them make better decisions.

SAVE TIME & SIMPLIFY

medical research

62% of surveyed users have saved 8 hours or more by conducting research with the LexisNexis MedMal Navigator tool.

THE MOST CRITICAL TASKS PERFORMED:

- ✓ Understand the medical issues relevant to a case
- ✓ Estimate case value and identify potential risks
- **✓ Locate and research** expert witnesses
- Determine the standard of care and catch deviations
- ✓ Capture the facts on all parties involved in a case
- **✓ Conduct** comprehensive legal research

SEE WHY ATTORNEYS & PARALEGALS RELY ON MEDMAL NAVIGATOR



The full view of any case involves the very factors that MedMal [Navigator] addresses, the understanding of the medicine, the view of other practitioners and the assessment of the risks of litigating a case.

Michael Brown, Attorney, Mike Brown Law

FIND OUT MORE
Call 800.628.3612

*Third party TechValidate® survey issued to MedMal Navigator customers, January, 2017. † Based on a comparison of legal research providers, February 2017.